AIM ImmunoTech

AIM ImmunoTech P/TBV

The Price to Tangible Book Value (P/TBV) of AIM ImmunoTech (AIM) as of Oct 16, 2026 is -0.43. In the previous year, Price to Tangible Book Value (P/TBV) was -1.09 — a change of -59.97% (higher).

P/TBV

-0.43

YoY

-59.97%

Last updated:

Price to Tangible Book Value (P/TBV) of AIM ImmunoTech is 2025 -0.43 . Price to Tangible Book Value (P/TBV) of AIM ImmunoTech was 2024 -1.09 . It decreases by -59.97% higher compared to the previous year.

The AIM ImmunoTech P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
1.00 USD
Jan 1, 2019
0.36 USD
Jan 1, 2020
0.07 USD
Jan 1, 2021
0.08 USD
Jan 1, 2022
0.12 USD
Jan 1, 2023
0.54 USD
Jan 1, 2024
-1.09 USD
Jan 1, 2025
-0.43 USD
The AIM ImmunoTech P/TBV history
YEARP/TBVYoY
-0.43-59.97%
-1.09-302.27%
0.54+361.14%
0.12+50.31%
0.08+8.91%
0.07-80.34%
0.36-63.75%
1.00+84.07%
0.54+86.44%
0.29+33.39%
0.22+23.75%
0.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AIM ImmunoTech Stock analysis

What does AIM ImmunoTech do? AIM ImmunoTech Inc is a biotechnology company based in Ocala, Florida, operating within the health care sector. The company focuses on the clinical development of drug therapies utilizing natural immune system enhancing technologies for treating viral and immune-based disorders. It employs 31 full-time staff members. AIM ImmunoTech's primary products include Alferon N Injection, approved for intralesional treatment of refractory or recurring external genital warts in patients over 18, and Ampligen, which is under clinical development for Chronic Fatigue Syndrome (CFS). The company also develops Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon. AIM ImmunoTech went public on July 12, 1996, with its ticker symbol AIM and ISIN US00901B3033. Its website is hemispherx.net. The company's operations are centered around research and development activities related to Ampligen and other drugs in development, alongside sales and marketing of Alferon. The firm's activities are primarily directed toward addressing chronic viral and immune-related conditions through innovative therapeutic approaches. AIM ImmunoTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AIM ImmunoTech stock

Price to Tangible Book Value (P/TBV) of AIM ImmunoTech is -0.43 in 2025.

Price to Tangible Book Value (P/TBV) of AIM ImmunoTech changed from -1.09 to -0.43, representing a -59.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) AIM ImmunoTech since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s AIM ImmunoTech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — AIM ImmunoTech

All Key Metrics — AIM ImmunoTech